Clinical Trial Update: A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating vismodegib with concurrent chemotherapy and bevacizumab as first-line therapy for metastatic colorectal cancer. The trial completed and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Vismodegib (Vismodegib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-07-03